Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 77

1.

Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study.

Shigiyama F, Kumashiro N, Miyagi M, Ikehara K, Kanda E, Uchino H, Hirose T.

Cardiovasc Diabetol. 2017 Jul 6;16(1):84. doi: 10.1186/s12933-017-0564-0.

2.

Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care-based cohort study, with economic assessment of patient outcomes.

Gordon J, McEwan P, Evans M, Puelles J, Sinclair A.

Diabetes Obes Metab. 2017 May;19(5):644-653. doi: 10.1111/dom.12867. Epub 2017 Feb 23.

3.

Comparative Effectiveness of Second-Line Agents for the Treatment of Diabetes Type 2 in Preventing Kidney Function Decline.

Hung AM, Roumie CL, Greevy RA, Grijalva CG, Liu X, Murff HJ, Ikizler TA, Griffin MR.

Clin J Am Soc Nephrol. 2016 Dec 7;11(12):2177-2185. Epub 2016 Nov 8.

4.

Management of newly treated diabetes in Medicare beneficiaries with and without heart failure.

Cooper LB, Mi X, Mentz RJ, Green JB, Anstrom KJ, Hernandez AF, Curtis LH.

Clin Cardiol. 2017 Jan;40(1):38-45. doi: 10.1002/clc.22603. Epub 2016 Oct 26.

5.

Comparative Effectiveness of Diabetic Oral Medications Among HIV-Infected and HIV-Uninfected Veterans.

Han JH, Gordon K, Womack JA, Gibert CL, Leaf DA, Rimland D, Rodriguez-Barradas MC, Bisson GP.

Diabetes Care. 2017 Feb;40(2):218-225. doi: 10.2337/dc16-0718. Epub 2016 Sep 15.

6.

Metformin, Diabetes, and Survival among U.S. Veterans with Colorectal Cancer.

Paulus JK, Williams CD, Cossor FI, Kelley MJ, Martell RE.

Cancer Epidemiol Biomarkers Prev. 2016 Oct;25(10):1418-1425. Epub 2016 Aug 5.

7.

Differences in glycemic control across world regions: a post-hoc analysis in patients with type 2 diabetes mellitus on dual antidiabetes drug therapy.

Brath H, Paldánius PM, Bader G, Kolaczynski WM, Nilsson PM.

Nutr Diabetes. 2016 Jul 4;6(7):e217. doi: 10.1038/nutd.2016.25.

8.

Comparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users.

Gamble JM, Thomas JM, Twells LK, Midodzi WK, Majumdar SR.

Medicine (Baltimore). 2016 Jun;95(26):e3995. doi: 10.1097/MD.0000000000003995.

9.

Effectiveness of vildagliptin versus other oral antidiabetes drugs as add-on to sulphonylurea monotherapy: Post hoc analysis from the EDGE study.

Prasanna Kumar KM, Phadke U, Brath H, Gawai A, Paldánius PM, Mathieu C.

Prim Care Diabetes. 2016 Dec;10(6):452-458. doi: 10.1016/j.pcd.2016.06.001. Epub 2016 Jun 25.

10.
11.
12.

Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis.

Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, Chu Y, Iyoha E, Segal JB, Bolen S.

Ann Intern Med. 2016 Jun 7;164(11):740-51. doi: 10.7326/M15-2650. Epub 2016 Apr 19. Review.

PMID:
27088241
13.

Recent trends in the use of antidiabetic medications from 2008 to 2013: A nation-wide population-based study from Taiwan.

Ou HT, Chang KC, Liu YM, Wu JS.

J Diabetes. 2017 Mar;9(3):256-266. doi: 10.1111/1753-0407.12408. Epub 2016 May 30.

PMID:
27062145
14.

The rationale, design, and baseline characteristics of PREVENT-DM: A community-based comparative effectiveness trial of lifestyle intervention and metformin among Latinas with prediabetes.

Perez A, Alos VA, Scanlan A, Maia CM, Davey A, Whitaker RC, Foster GD, Ackermann RT, O'Brien MJ.

Contemp Clin Trials. 2015 Nov;45(Pt B):320-327. doi: 10.1016/j.cct.2015.10.011. Epub 2015 Oct 24.

15.

Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective.

Charokopou M, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K, Postema R, Townsend R, Roudaut M.

BMC Health Serv Res. 2015 Nov 5;15:496. doi: 10.1186/s12913-015-1139-y.

16.

The changing face of diabetes in youth: lessons learned from studies of type 2 diabetes.

Hannon TS, Arslanian SA.

Ann N Y Acad Sci. 2015 Sep;1353:113-37. doi: 10.1111/nyas.12939. Epub 2015 Oct 8. Review.

17.

Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France.

Roussel R, Martinez L, Vandebrouck T, Douik H, Emiel P, Guery M, Hunt B, Valentine WJ.

J Med Econ. 2016;19(2):121-34. doi: 10.3111/13696998.2015.1100998. Epub 2015 Nov 5.

PMID:
26413789
18.

Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.

Thomsen RW, Baggesen LM, Søgaard M, Pedersen L, Nørrelund H, Buhl ES, Haase CL, Johnsen SP.

Diabetologia. 2015 Oct;58(10):2247-53. doi: 10.1007/s00125-015-3698-1. Epub 2015 Aug 16.

PMID:
26277380
19.

Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study.

Seong JM, Choi NK, Shin JY, Chang Y, Kim YJ, Lee J, Kim JY, Park BJ.

PLoS One. 2015 May 20;10(5):e0124287. doi: 10.1371/journal.pone.0124287. eCollection 2015.

20.

Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China.

Gu S, Deng J, Shi L, Mu Y, Dong H.

J Med Econ. 2015;18(10):808-20. doi: 10.3111/13696998.2015.1049542. Epub 2015 Jul 1.

PMID:
25950193

Supplemental Content

Loading ...
Support Center